Cancer is considered as one of the most challenging health care problems. Though there are many approved drugs that can be used for cancer therapy, drug resistance and delivery are among of the barriers of the treatment. In addition, pathological characteristics of tumors and their abnormal blood vessel architecture and function also reduce the efficiency of the conventional cancer treatment. Therefore, looking for techniques that can increase the efficacy of the therapy such as nanoparticles (NPs) is vital. NPs have many properties such as their small size, ability to load various drugs and large surface area, and ability to increase the absorption of conjugated. Therefore, the NPs have been considered as excellent tumor-targeting vehicles. The recent nanoscale vehicles include liposomes, polymeric nanoparticles, magnetic nanoparticles, dendrimers, and nanoshells; lipid-based NPs have been used as conjugates. There are few examples of approved conjugated anticancer NPs including AmBisome® (amphotericin B liposomal) and Doxil® (liposomal doxorubicin). There are many other conjugated anticancer drugs at different stages of clinical trials for treatment of various cancers. This review will discuss the properties of different NPs in cancer treatment and their benefits of overcoming multidrug resistance. In addition, recent advances of using nanomedicine in different approaches of cancer treatment such as chemotherapy, radiotherapy, and immunotherapy will be highlighted in this review.
1. Introduction
There are several therapeutic methods that have been used to treat tumors and their surrounding environments. An example of these strategies is chemotherapy, which was first tried in 1942 when Louis Goodman and his colleagues tested using nitrogen mustard in treatment of non-Hodgkin’s lymphoma. After that, many chemotherapeutic drugs have been used to eradicate cancer progression [1]. Nowadays, there are many examples of chemotherapeutic agents that have been used to control different cancers in clinic such as doxorubicin, paclitaxel, gemcitabine, and cisplatin [1]. However, chemotherapy has helped in the improvement of cancer therapy of patients; in most cases, cancer with a more progressive stage normally occurs, and usually, multidrug resistance takes place. Targeting the surrounding environment of tumors also has been tried, since cancer cells depend primarily on oxygen and angiogenesis for survival and metastasis [2]. Radiotherapy is another example of a method for eradicating cancer cells, since cancer cell is more susceptible for damaging compared to normal cells [3]. Gene therapy and immunotherapy have been also used for cancer therapy [4, 5]. However, most of them are associated with side effects, resistance, or recurrence after initial treatment [6].
The failure of chemotherapy in the clinic is mainly due to different extents of multidrug resistance (MDR) results with approximately 90% of cancer patients died [7]. MDR occurs when tumor cells develop resistance to structurally and functionally unrelated classes of chemotherapeutic agents leading to drug inactivation and/or drug efflux from cancer cells leading to obstacle of the treatment [8]. There are several report hypotheses of the molecular mechanisms of MDR, mainly including increasing efflux of membrane transport proteins, detoxification by reducing the drug activation and potentiating drug metabolism, alteration in drug targeting by enhancing the DNA repair mechanism, blocking apoptosis, and alteration of cell cycle regulation (Figure 1) [9]. All these mechanisms synergistically interact together to produce MDR. The modulation of membrane transport protein is one of the most effective mechanisms of resistance against the commonly used anticancer drugs. There are two approaches to decrease the intracellular accumulation of cytotoxic agents inside cancer cells either by reducing drug uptake and/or increasing extrusion of the chemotherapeutic molecules. Both mechanisms are mediated by ATP-binding cassette (ABC) proteins and transmembrane transporters [10]. Overexpression of P-glycoprotein (P-gp, MDR1, or ABCB1) which is the most common member of ABC proteins is responsible for the development of MDR. P-gp is consisting of two homologous halves, each containing six transmembrane domains (TMD) and a nucleotide-binding domain (NBD) [10].
Molecular mechanisms of multidrug resistance in cancer.
The common substrates of the P-gp transporter are including epipodophyllotoxins, Vinca alkaloids, taxanes, and anthracyclines that are currently involved in chemotherapeutic regimens [11]. Several approaches have been investigated to overcome the efflux pump either by inhibition of the function of P-gp using natural agents that act as P-gp inhibitors or by downregulation of MDR-1 gene expression [12, 13]. These approaches subsequently reverse MDR and inhibit the P-gp function, thus enhancing the therapeutic efficacy [14]. NP scan overcome all these mechanisms of MDR [15, 16].
Therefore, it is rational to find out a combination therapy with more precise technique to maximize the efficacy of the therapy and to overcome multidrug resistance in cancers. NP conjugation with chemotherapeutic drugs or using NPs during radiotherapy of cancer showed some promising outcome, with many of them approved for treatment of different cancer types [17]. The formulations of chemotherapeutical agents into nanoparticle have several advantages over the standard chemotherapy dosage form. The bioavailability of a low molecular weight drug is increased by its formulation in nanoparticle, whereas nanosized drug carrier minimizes their elimination through the liver and/or kidney [18]. The permeability and accumulation of chemotherapeutical nanoparticle are passively targeting the tumor tissue resulting in low systemic toxicity and increased drug concentration inside more than the treatment with standard chemotherapy [19]. This review will discuss the update of the use of NPs to overcome the resistance of cancer treatment.
2. Cancer Targeting with Conjugated Nanoparticles
NPs have been used to produce one or more of the followings actions. They prevent the degradation of the conjugated drug. They also improve its absorption through the epithelial diffusion that ultimately results in reaching the optimum concentration in a short time. NPs also alter the pharmacokinetic and distribution profile of the drug in the tissue and increase the intracellular efflux in cancer cells [20]. NPs are designed as active and passive targeting of anticancer drugs to deliver and elevate the intracellular anticancer concentration. Enhancing the permeability and retention effects of anticancer drugs is considered as passive targeting of NPs to the tumors. However, actively targeted NPs can be designed based on tumor microenvironment- and ligand-directed targeting to the tumor cells [21]. Therefore, as a unique inherent property of NPs to the solid tumors, the nanoparticle is considered as an excellent tumor-targeting vehicle. This effect makes the accumulation of NPs preferable at the tumor site. In addition, the multifunction of NPs allows targeting the tumor site that is directly connected to the main blood circulation [22]. This action considered as a major advantage of NPs against MDR mechanisms. There are several types of NPs which include lipid (NPs) and nanocapsules, polymeric (NPs), metal (NPs), dendrimers, and liposomes that will be discussed in detail in this review (Figure 2) [23].
Common drug targeting technology.
3. Can Be the Barriers for the Treatment of Tumors Overcome by Nanoparticles?
At the cellular level, the drug resistance is considered as a physiological barrier to the success of the anticancer drug. The penetration of chemotherapy to the solid tumor is difficult due to the pathological characteristics of the solid tumors that include abnormal blood vessel architecture and function, interstitial hypertension, lack of lymphatics, and dilated angiogenesis [24].
This microenvironment to certain extent contributes to the drug resistance results in decreasing in the drug accumulation and/or penetration to the solid tumor [25, 26]. Nevertheless, chemotherapy encounters another major barrier, i.e., multidrug resistance even after its penetration to the tumors. MDR remains the main challenge towards conventional chemotherapy during treatment of the common tumors [26].
Pharmaceutical history of the development of nanoparticle started with the first discovery of liposome [27]. Particle size is the most important properties of NPs that allows the NPs to be safely dosed via intravenous administration and to be the main choice of therapeutical approaches; this ultimately allows increasing the specificity of effective drugs and overcoming the resistance of tumors [28].
The therapeutic index of NPs has improved the potential of commonly used drugs through increasing the efficacy and decreasing the toxicity of the drug and keeping its concentration in the steady state over a long period of time [29]. Thus, drug-coated NPs should have long half-life to give the maximum effect. NPs increase the chemical’s solubility and stability to provide new effective drugs. The targeting of active sites of transporters or receptors is the main character of NPs because of their flexible surface chemistry that allows for potential conjugation of targeting ligands. Figure 3 shows the several mechanisms of NPs to improve drug delivery to the solid tumors [30]. On the other hand, several anticancer agents exhibit low specificity towards cancer cells. Hence, the adverse outcomes of chemotherapeutic agents diminish the effective dose to the tumor resulting in subtherapeutic to the toxic effects [31]. Therefore, the delivery of drugs to the solid tumors is still a difficult approach. The reticuloendothelial system (RES) that known as “mononuclear phagocytes” is the major defense system in the bloodstream of the body that rapidly removes NPs from the blood [32].
Nanotechnology against multidrug resistance.
Therefore, it has been considered as a main obstacle for the circulated nanoparticles. RES recognizes the NPs as foreign bodies. Hydrophilic and flexible polymers can coat the NPs from the opsonins hence avoid the uptake of NPs by the RES [33]. Poly(ethylene oxide) and poly(propylene oxide) or their combinations are the most commonly used polymers that covalently grafted, entrapped, and adsorbed on the surface of nanoparticles. The degree of block binding of NPs to opsonins is variable depending on the thickness of the layer that coats the nanoparticles, coating strategies, polyethylene glycol PEG molecular weight, surface chain density, and conformation [34]. The development of lipid-based nanoparticle systems of anticancer drugs has advantages including the improved drug delivery, low toxicity, enhanced solubility, increased loading and protection of drugs, prolonged circulation, targeting delivery, and controlled release [35]. Liposomes, micelles, nanoemulsions, nanocapsules, and solid lipid NPs are common types of lipid-based NPs that are administered by different routes, e.g., oral, topical, and parenteral [23]. NPs such as liposomes, polymeric, magnetic, silica, and gold NPs used to prepare MDR inhibitors through increasing drug efflux altered metabolism, activating DNA repair and changing apoptotic pathways (Figure 3).
4. Overcoming MDR Using NPs and the Possible Mechanisms
Several approaches attempting to overcome drug resistance have been developed including NPs (Figure 3). Some of the common examples of preparation that formulated chemotherapy in NPs are summarized in Table 1.
The formulated NPs of chemotherapy.
Nanoparticle
Medicinal ingredients
Generic name
Cancer type
Reference
Liposome NP
Doxorubicin
Doxil
Kaposi sarcoma, ovarian cancer, and multiple myeloma
[36]
Doxorubicin
Myocet
Metastatic breast cancer
[36]
Doxorubicin
MM-302
HER-2-positive breast cancer
[37]
Doxorubicin
Anti-EGR liposome
Many solid cancers
[38]
Doxorubicin
ThermoDox
Hepatocellular carcinoma
[39]
Vincristine sulfate
Marqibo
Acute lymphoblastic leukemia
[36]
Irinotecan
MM-398
Metastatic pancreatic cancer
[40]
Irinotecan
CPX-1
Advanced colorectal cancer
[41]
Paclitaxel
EndoTAG-1
Pancreatic cancer, liver metastases, and HER2-negative breast cancer
[42, 43]
Cisplatin
Lipoplatin
Non-small-cell lung cancer
[44]
siRNA against EPHA2
siRNA-EPHA2-DOPC
Late-stage cancers
[45]
siRNA against PLK1
TKM-080301
Late-stage hepatocellular carcinoma
[46]
MUC1 antigen
Tecemotide
Non-small-cell lung cancer
[47]
HER2 antigen
dHER2+AS15
Breast cancer
Multicancer-associated antigens
DPX-0907
Ovarian, breast, and prostate cancers
[48]
Melanoma antigens
Lipovaxin-MM
Malignant melanoma
[49]
Albumin NP
Paclitaxel
Abraxane
Breast, lung, and pancreatic cancers
[36]
Lipid NP
siRNA against PLK1
TKM-080301
Advanced hepatocellular carcinoma
[50]
siRNA against MYC
DCR-MYC
Hepatocellular carcinoma
[51]
siRNA against KSP
ALN-VSP02
Solid tumors
[52, 53]
shRNA against stathmin 1
pbi-shRNA STMN1 LP
Late-stage cancers
[54]
Colloid gold NP
TNF, several chemotherapies
CYT-6091 AuNPs
Late-stage cancers
[55, 56]
Polymeric micelle
Paclitaxel
Genexol-PM
Breast cancer and non-small-cell lung cancer
[36]
5. Common NPs That Have Been Used in Cancer Therapy5.1. Liposomes
Liposomes are colloidal drug delivery systems normally composed of phospholipids. It is consisting of the concentric bilayer vesicles with layers of aqueous media separating the lipid layers. The small unilamellar vesicles have particle size range of 20–80 nm and consist of a lipid outer layer with an aqueous core. The type of phospholipids determined the charge of the surface of the liposomes (charged or uncharged) [57]. Both hydrophobic and hydrophilic drugs are incorporated in liposomes. The hydrophobic drug is dissolved in the lipid layers, while hydrophilic drugs resided remain in the aqueous core. Several liposomal drugs are now marketed including AmBisome® (amphotericin B), Doxil® (doxorubicin hydrochloride), and Visudyne® (verteporfin). These preparations inhibit direct P-gp efflux or bypassing P-gp through an endocytosis pathway [58]. A liposome is a vesicle which consists of phospholipid membrane and can be filled with chemotherapy. Phospholipids have hydrophilic head and hydrophobic tail. Liposome is one of the most common NPs that is approved for treatment of cancer [59–61]. Liposomes are usually administrated as a potential targeting and delivery tool of the chemotherapy because liposomes able to minimize elimination, increase the targeting, and reduce the toxic side effect of the chemotherapeutical agents [62]. Doxorubicin is one of the commercial available chemotherapies in a liposome dosage form (e.g., Doxil and Myocet) [63]. Pharmaceutically, the liposome improves the pharmacokinetic and pharmacodynamic properties of the drug used; hence, the survival of cancer patients increases compared with parenteral drug treatment.
5.2. Polymer, Lipid Nanocapsules, and Nanoparticles
Nanocapsules have polymeric membrane (polymers or a combination of hydrophilic/lipophilic surfactants) that covers the liquid core (essential oils and triglycerides). The hydrophobic drugs are loaded in the lipid core and considered as a reservoir allowing a high drug loading with sustained release. Therefore, nanocapsules are ideal for lipid-soluble drug preparation [64]. Lipid NPs (or nanocapsules) are commonly used to overcome P-gp-mediated drug resistance [65]; an example of that is the use of nanosponge [66]. In vivo, polyalkylcyanoacrylate NPs can reverse P-gp activity by an endocytosis process [67]. Polyisohexylcyanoacrylate (PIHCA) chemotherapy NPs showed more cellular uptake and cytotoxicity than free drugs in resistant cells. The mechanism of delivery of these NPs is by the changing the positive charge of drugs to ion pair with cyanoacrylic acid (a nanoparticle degradation product) increasing its diffusion across cell membranes [68]. A new polymer-lipid hybrid nanoparticle (PLN) system was used to bypass P-gp, leading to improved uptake and cytotoxicity of chemotherapy in resistant cells [67]. Drug-loaded sodium bis(2-ethylhexyl) sulfosuccinate (AOT)-alginate NPs significantly increased the chemotherapy cytotoxicity in resistant cells and overcome P-gp-mediated drug resistance [69].
5.3. Polymer-Drug Conjugates
Poly(N-[2-hydroxypropyl]methacrylamide) (polyHPMA) and HPMA copolymers are water-soluble, nonimmunogenic synthetic polymers. HPMA copolymer-chemotherapeutic drug conjugates exhibit potent effect to overcome MDR [70, 71]. The endocytosis pathway is the mechanism of action whereas the conjugation of polymer-drug was hydrolyzed by enzymatic reaction in the lysosome of the cells, resulting in the release of the drug from the conjugate. The MDR1 expression was downregulated by HPMA conjugates and decreases the resistance against Taxol of resistant cells [72, 73]. Additional mechanisms are inhibition of detoxification genes encoding glutathione and UDP, induction of apoptosis signaling pathways, and downregulation of DNA repair [74]. The most commercially available albumin-based NP is paclitaxel (nab-paclitaxel; Abraxane) [75]. Albumin-based nanomedicine is able to formulate the hydrophobic chemotherapy in injection with broad-spectrum doses (high dose) and quickly reaches to the maximum concentration of drugs in plasma with higher bioavailability [76]. Thus, nab-paclitaxel (IV) is degraded into paclitaxel and albumin without any significant change in pharmacokinetic or tissue distribution of the chemotherapeutical agent [77]. In addition, by increasing the time of treatment with nab-paclitaxel (for several weeks), the rate of response and progression of the breast cancer patients were significantly increased more than the standard paclitaxel treatment [78].
5.4. Pluronic Micelles
The micelles are naturally present in the body that utilize the endogenous surfactant bile salts to complete lipid digestion [79]. Micelles functionally facilitate the absorption of water-insoluble fat and fat-soluble vitamins [80]. Their size is normally within in a range between 5 and 100 nm; amphiphilic molecules consist of a core: hydrophobic fragments and shell and hydrophilic moieties [81]. Water-insoluble drugs are usually intravenously administrated with an adjuvant solubilizing agent such as ethanol, which mainly has common toxic side effects [82]. The micelle nanoparticle formulation of these hydrophobic drugs is usually used to avoid the addition of the harmful adjuvant [83].
Folate-conjugated poly(ethylene glycol)-b-copolycarbonates and methoxy poly(ethylene glycol)-b-copolycarbonates loaded with doxorubicin improve the cytotoxicity of doxorubicin via FA receptor-mediated endocytosis [84]. Clinical trials were used to treat metastatic GIT adenocarcinoma using SP1049C-doxorubicin micelles of pluronic L61 and F127. The accumulation of doxorubicin in tumors was more than free doxorubicin with normal distribution of polymer in normal tissues [85, 86]. The mechanism of action of micelles is changing the structure of the membrane, decreasing membrane fluidization, and inhibiting function and expression of efflux transporters, such as P-gp and MRPs [87–90]. These subsequently sensitize resistant cancer cell to the chemotherapeutic agents [91], increasing the proapoptotic [92], decreasing the levels of glutathione (GSH) and glutathione-S-transferase (GST) activity, inhibiting the mitochondrial respiratory chain [92], decreasing oxygen consumption [93], and decreasing both mitochondrial membrane potentials [94], and the production of reactive oxygen species and release of cytochrome C in MDR cells are additional mechanisms [95, 96].
6. NPs in Chemotherapeutic Approaches of Cancer Treatment
Conjugated NPs have been applied in many disciplines of cancer treatment approaches. The followings are examples of the methods that have been combined with nanoparticles, in order to overcome multidrug resistance and/or to increase the sensitivity of the treatment.
6.1. NPs Conjugated with Topoisomerase Inhibitor Drugs
Topoisomerase inhibitors work through molecularly targeting topoisomerase enzymes that are essential for underwinding DNA during replication which leads to cell cycle arrest at G1 and G2 and apoptosis ultimately after failing DNA damage repair [97]. FDA has considered doxorubicin as one of the most effective chemotherapeutic drugs [98]. It introduces into DNA and RNA polymerase, which eventually stopped their actions. Doxorubicin can also induce apoptosis through activation of adenosine 5′ monophosphate-activated protein kinase (AMPK) that activates downstream targets such as p53, c-Jun N-terminal kinase (JNK), and mammalian target of rapamycin complex 1 (mTORC) [99–102]. Despite of anticancer effects of doxorubicin, resistance in some tumors has been shown. Another example of a chemotherapy drug that targets isomerase is irinotecan. It is a semisynthetic analogue of a camptothecin that is firstly obtained from the Camptotheca acuminata tree. It is a chemotherapeutic drug that initiates cell apoptosis through targeting topoisomerase I. It exhibits a potent antiproliferative activity against a different cancer types [103]. Same as doxorubicin, irinotecan interferes with the Topo-I-DNA complex resulting in twisting of DNA and DNA damage through double-strand breaks [104]. Conjugation of NPs with topoisomerase targeting drugs has shown successful in targeting many cancers; for example, Doxil is a liposomal doxorubicin conjugation that is approved by FDA for treatment of Kaposi sarcoma, ovarian cancer, and multiple myeloma [36] and Myocet is approved by European and Canadian for treatment of metastatic breast cancer [36]. M-302 is in clinical trial for treatment of human epidermal growth factor receptor 2 (HER2) breast cancer [52] and anti-EGFR immunoliposome loaded with doxorubicin in clinical trial I for treatment of solid tumors [38], and ThermoDox, is liposome conjugated with doxorubicin for treatment of hepatocellular carcinoma in clinical trial III [39]. Another example for topoisomerase conjugated with NPs is MM-398 that is liposome conjugated with irinotecan, which is approved by FDA for metastatic pancreatic cancer treatment [40], and CPX-1 is in phase II for treatment of advanced colorectal cancer [41]. Conjugation of NPs with cisplatin has been used to increase the efficiency of cancer cell targeting and to reduce side effect of this drug. Lipoplatin, for example, is pegylated liposome that is conjugated with cisplatin for treatment of non-small-cell lung cancer (NSCLC), and it is now in phase III [44]. The combination of both chemotherapies such as doxorubicin and P-gp inhibitor such as verapamil in liposome formulation showed more cytotoxic effect than a single drug in both in vitro and in vivo resistant models [105]. Human transferrin (Tf) was used to potentiate the targeting effects of liposomes on Tf receptors. In resistant leukemia K562 cells (overexpressed with Tf receptor+), Tf-conjugated coloaded liposomes showed highly cytotoxic than both nontargeted coloaded liposomes and Tf-conjugated doxorubicin liposomes. Hence, the TfR-targeted liposomes coloaded with doxorubicin and verapamil were able to reverse drug resistance and selectively target cancer cells [106]. pH-sensitive liposome doxorubicin (SpHL-DOX) has been reported to reduce the serious cardiotoxic effects of DOX in preclinical trial [107].
6.2. NPs Conjugated with Tubulin Assembly Inhibitor Drugs
Tubulin assembly targeting drugs are group of agents that interfere with mitotic assembly of tubulin and subsequently induce chromosome segregations and cell death eventually [108]. Paclitaxel is an example of these chemotherapeutic drugs that has been used for cancer treatment [108]. Vincristine sulfate (vincristine) is another example of a tubulin dynamic targeting chemotherapeutic drug that suppresses cancer cell proliferation through blocking mitosis via inhibition tubulin formation [109–111]. The inhibition of mitosis occurs between metaphase and anaphase of a cell cycle, which results in tubulin depolymerization [112, 113]. This leads to chromosome condensation and later dissociation but stay attached with the centromeres [114]. Vincristine (VCR) is used widely for lymphoma and leukemia treatment [115]. It has been reported that the overexpression of P-glycoprotein (P-gp) on several cancer cell membranes, e.g., leukemia, colorectal, and breast cancers, leads to cellular resistance to VCR [116]. Conjugation of paclitaxel with NPs augmented drug delivery, therefore, increases treatment effectiveness. Works on breast cancers with a metastatic stage shows the dramatic eradication of metastasis after administration of paclitaxel in complex with NPs and shRNA [117]. It effectively delivered the drug and RNA that suppressed metastasis [118]. Using paclitaxel loaded in pax NPs during ovarian tumor surgery effectively reduced tumor relapse. Combination of chemotherapy with NPs has shown promising result in boosting cancer treatment. For example, Abraxane is albumin bound to paclitaxel approved by FDA for treatment of breast, lung, and pancreatic cancers [36]. Genexol-PM, which is polymeric micelle conjugated with paclitaxel, is approved in Korea for breast cancer treatment [36], NK-105 conjugated with polymeric micelle is for metastatic breast cancer treatment in phase III [119], EndoTAG-1 is liposomal paclitaxel for pancreatic, hepatic, and breast cancers [42, 43], and Marqibo, which is vincristine sulfate conjugated with liposome, is approved by FDA for acute lymphoblastic leukemia treatment [36].
6.3. NPs Conjugated with Drugs That Target DNA Replication
There are many chemotherapeutic drugs targeting DNA replication. For example, cisplatin is a chemotherapeutic drug that has had a wide influence in cancer therapy [120]. It works through interfering with DNA replication primarily via its interaction with purine bases in DNA to form a DNA protein crosslink [120]. Cisplatin-induced DNA damage activates many cellular signaling. It activates cell cycle checkpoints that transitory induces the S phase and subsequently inhibits Cdc2-cyclin A to induce G2 arrest [121, 122]. It also induces cyclin-dependent kinase 4 (Cdk4) inhibitor p16INK4A, which results cell cycle arrest at G1 [123].
The limitations of the therapeutic efficacy of cisplatin in cancer treatment are mainly due to drug resistance and systemic side effects in treated patients. Cisplatin resistance is correlated to the increase in the intercellular levels of glutathione (GSH). Recently, unique NPs composed of cisplatin prodrug and poly(disulfide amide) polymers with a high disulfide density which reverse cisplatin resistance in cancer cells were developed [124]. The suggested mechanism of this nanoparticle platform is GSH scavenging process by a disulfide group of polymers. Furthermore, TAT-ASA-MNPs@CDDP nanoparticle was prepared by condensation of aldehyde with the amino group and then coordinated with cisplatin which exhibited more cytotoxic and apoptotic effect than prodrug [125].
There are other few examples of conjugated cisplatin with NPs. Conjugation of cisplatin with polymeric micelle has been used under a NK-105 trade name. This compound has been tested for non-small-cell lung cancer, and it is in phase III [44].
7. NPs in Nonchemotherapeutic Approaches of Cancer Treatment
There are other strategies that have been used for cancer treatment other than chemotherapy. Radiotherapy, for example, has been used in cancer therapy for many decades that has shown a benefit for some cancer types and on cancer patient’s survival [3]. For end-stage tumor cases, radiotherapy is a preferable treatment [126]. Radiation induces double-strand DNA damage either through ionization or through increasing free radical production within cells resulting in apoptosis [127]. It induces many signaling pathways that are essentials for cell death, including the p53 pathway. Inhibition of upstream signaling proteins of DNA damage such as ATM and ATR has shown implication in increasing cancer cell sensitivity towards radiotherapy [128–130]. NPs, such as chlorin e6-loaded chitosan, improved photodynamic cancer therapy. The use of NPs in radiotherapy for cancer treatment has been tested before; Nanobiotix (NBTXR3) hafnium oxide is administrated systematically and once targeted cancer cells; they are activated by radiotherapy resulting in energy release and destroying cancer cells [131]. It is in phase III for soft tissue sarcoma treatment [131]. Highly biocompatible chlorin e6-loaded chitosan nanoparticles have been shown to improve photodynamic cancer therapy [132].
Immune therapy is also among the approaches that has been used for cancer treatment. After initial cancer transformation in premalignant tumors, immune cells can effectively eliminate these cells in a process called “immune surveillance.” However, impairment in this mechanism could result in malignancy [133]. Since the immune system can clear cancer cells in an early stage, scientists tried to treat cancer through boosting of the immune system. Many immunotherapy strategies have been approved for treatment of different cancer types, for example, sipuleucel-T for prostate cancer treatment [5] and CTLA-4 antibody for melanoma [134]. Some immunotherapy includes stimulating immune cells through cancer antigen vaccination, such as interleukin-2 (IL-2) and interferon-α (IFNα), or using dendritic cells for therapy enhancement [135–137]. Combination of gene therapy and NPs has been tested for cancer therapy. Tecemotide, for example, for non-small-lung cancer treatment in clinical trial III, is a transmembrane glycoprotein Mucin 1 (MUC1) antigen conjugated with liposome to induce immune response against cancer cells [47]. dHER2+As15 is in clinical trial II; it is a recombinant HER2 and AS15 antigen for treatment of metastatic breast cancer [138]. DPX-0907 is polytumor-related antigens linked with liposome in clinical trial I for late-stage ovarian breast and prostate tumors [48]. Lipovaxin-MM is in clinical trial I, and it is a combination of a melanoma antigen conjugated with liposome for malignant melanoma treatment [49]. JVRS-100 is a conjugated drug between lipid nanoparticle and DNA for relapsed leukemia; it is in phase I [139]. CYT-6091 is another example of a combination between tumor necrosis factor (TNF) antigen and colloid gold nanoparticle for treatment of late-stage solid tumors, and it is in clinical trial I [55].
Gene therapy is a method of delete, modify, or replace mutated genes in target host cells. In cancer research, gene therapy has received attention since cancer cells have mutated gene(s) that results in uncontrolled proliferation [4]. Therefore, ability to introduce intact genes to cancer cells or dormant stem cells can modulate malignancy. Transferring genetic materials into host cells can be conducted using viral, bacterial vectors, or nonviral vectors such as liposome and nanoparticles [140]. There are examples of nanoparticle drug conjugation genetic materials for gene therapy of cancer. SGT53, for example, is Tfr-targeting liposome that is conjugated with plasmid coding for wild-type p53 for treatment of pancreatic cancer in phase II [141, 142], and PNT2258 drug is a liposome nanoparticle conjugated with oligonucleotide against BCL2 for non-Hodgkin lymphoma and diffuse B-cell lymphoma in phase II [143, 144]. SNS01-T is polyethylenimine NPs linked with eIF5A plasmid for recurrent B cell malignancies in phase I/II [145]. Atu027 is a liposomal particle conjugated with small interfering RNA (siRNA) N3 kinase for pancreatic cancer treatment in phase I/II [50]. TKM-080301 is a lipid nanoparticle conjugated with polo-like kinase (PLK1) siRNA for hepatocellular carcinoma and neuroendocrine tumors in phase I/II [46, 146], discontinue clinical development of DCR-MYC; it is also lipid nanoparticle conjugated with siRNA against MYC for hepatocellular carcinoma treatment in phase I/II [51]. CALAA-01 is polymeric nanoparticle conjugated with siRNA against ribonucleotide reductase M2 for many solid tumor treatment in phase I [147]. ALN-VSP02 is a lipid nanoparticle conjugated with siRNA against kinesin spindle protein (KSP) and vascular endothelial growth factor A (VEGFA) for solid tumor treatment in phase I [52, 53]. siRNA-EPHa2-DOPC is a liposome conjugated with sirRNA against ephrin type-A receptor 2 (EphA2) for late-stage solid tumor treatment in phase I [45]. pbi-shRNA STMN1LP is lipid nanoparticle against stathmin 1 for many solid tumor treatment in phase I [54]. Chen et al. reported that the multidrug delivery devices by combination of novel liquid crystalline self-assembled nanocarriers with baicalin (BAI) and Brucea javanica oil (BJO) synergistically enhanced the anticancer activity through induction of apoptosis in human lung carcinoma cell line A549 [66].
Recently, novel pH-sensitive prodrug nanoparticles were prepared using self-assembly of a synthetic amphiphilic macromolecular prodrug resulting in the improvement of the selective codelivery of doxorubicin (Dox) and curcumin (Cur) into the human breast cancer cell line MCF-7 with an improved cardiotoxicity profile on an in vivo zebrafish model compared to free Dox [148]. Furthermore, novel disulfide-crosslinked sodium alginate nanoparticles with doxorubicin were prepared and enhanced the doxorubicin release by triggered glutathione and showed a selective cancer cell cytotoxicity on Hep-G2 and HeLa cells, safe on healthy human liver L-O2 cells, and no cardiotoxicity in an in vivo zebrafish model [149].
8. Conclusions
Overcoming the drug resistance in cancer treatment is an important approach and has become the greater interest in the last years. The fast improvement of the drug delivery system and development of the nanotechnology provide the possibility of a more potential strategy for drug resistance in cancer. The development of NPs might provide a new strategy for the treatment cancer therapy. However, there are several challenges that should be overcome, for example, off targeting of normal cells that share the same surface proteins of cancer cells; hence, selective targeting of cancer cells is not guaranteed. Therefore, identifying the specific surface marker for cancer cells is crucial for a targeted therapy of tumor [150]. An example of high specific NPs is MM-398, which successfully targets cancer cells via the acidity of the tumor microenvironment. This drug inhibits the DNA replication machinery of highly dividing cells such as cancer cell. On the other hand, some normal cells are dividing in the acidic environment such as epithelial cells of the stomach. This explains the digestive associated side effects of the drug. Therefore, high selective ligands of cancer cells could limit these side effects. The challenge of nanomedicine also is extended to its production quality. Reproducibility of NPs at large-scale production is still difficult, especially synthesis of homogenous sets of the drug. Further, NPs need a special circumstance for production and storage. Hence, at each phase of NP production quality control should be performed to check the efficacy and reproducibility of NPs. Moreover, during the development of drugs in the laboratory, some changes in law sometimes take place. Therefore, groups such as Nanotechnology Characterization Laboratory should increase the collaboration between committees, scientists, and laboratories to support the assessment of nanomedicine legislation [151]. So, more work should be conducted in order to overcome these challenges. The solution is possible, but it requires a collaborative work between scholars, governments, and pharmaceutical companies to pave the way for the successful usage of NPs in cancer therapy. Nanoparticle formula loaded with chemotherapy has been designed to overcome the limitations associated with conservative drugs such as severe cytotoxic side effects and the variation in therapeutical response. Many nanomedicines have been approved by FDA and shown acceptable performance in clinical practice. However, the therapeutic efficacies cannot be improved. The future perspective of stimuli-responsive nanoparticles can be achieved by wide array of desirable properties including pH variations, redox potential, enzymatic activation, thermal gradients, magnetic fields, light, and ultrasound (US) or can even be responsive to dual or multicombinations of different stimuli that can be eventually developed for safe and efficient cancer therapy.
Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.
ChabnerB. A.RobertsT. G.Jr.Chemotherapy and the war on cancer200551657210.1038/nrc15292-s2.0-11144242211SaggarJ. K.YuM.TanQ.TannockI. F.The tumor microenvironment and strategies to improve drug distribution2013315410.3389/fonc.2013.001542-s2.0-84891053440PriseK. M.New advances in radiation biology200656315616110.1093/occmed/kql0102-s2.0-33646262346AmerM. H.Gene therapy for cancer: present status and future perspective2014212710.1186/2052-8426-2-27TopalianS. L.WeinerG. J.PardollD. M.Cancer immunotherapy comes of age201129364828483610.1200/jco.2011.38.08992-s2.0-84555218419FrankK. M.HogarthD. K.MillerJ. L.MandalS.MeaseP. J.SamulskiR. J.WeisgerberG. A.HartJ.Investigation of the cause of death in a gene-therapy trial2009361216116910.1056/nejmoa08010662-s2.0-67650497832XueX.LiangX. J.Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology201231210010910.5732/cjc.011.103262-s2.0-84857973669MoitraK.Overcoming multidrug resistance in cancer stem cells20152015863574510.1155/2015/6357452-s2.0-84948753065GottesmanM. M.Mechanisms of cancer drug resistance200253161562710.1146/annurev.med.53.082901.1039292-s2.0-0036176510ZhangX. D.ZhaoK. X.YangZ. M.Identification of genomic ATP binding cassette (ABC) transporter genes and Cd-responsive ABCs in Brassica napus201866413915110.1016/j.gene.2018.04.0602-s2.0-85046170571WinkM.AshourM. L.El-ReadiM. Z.Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents2012313010.3389/fmicb.2012.001302-s2.0-84867623825EidS. Y.El-ReadiM. Z.WinkM.Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters2012191197798710.1016/j.phymed.2012.05.0102-s2.0-84865222831El-ReadiM. Z.EidS.AshourM. L.TahraniA.WinkM.Modulation of multidrug resistance in cancer cells by chelidonine and Chelidonium majus alkaloids2013203-428229410.1016/j.phymed.2012.11.0052-s2.0-84873710000ShabbitsJ. A.KrishnaR.MayerL. D.Molecular and pharmacological strategies to overcome multidrug resistance20011458559410.1586/14737140.1.4.5852-s2.0-0035559193WangY.DouL.HeH.ZhangY.ShenQ.Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance201411388589410.1021/mp400547u2-s2.0-84901743691WangY.LiJ.ChenJ. J.GaoX.HuangZ.ShenQ.Multifunctional nanoparticles loading with docetaxel and GDC0941 for reversing multidrug resistance mediated by PI3K/Akt signal pathway20171441120113210.1021/acs.molpharmaceut.6b010452-s2.0-85019011561Laprise-PelletierM.SimãoT.FortinM. A.Gold nanoparticles in radiotherapy and recent progress in nanobrachytherapy2018716, article 170146010.1002/adhm.2017014602-s2.0-85046447695MatsumuraY.Poly (amino acid) micelle nanocarriers in preclinical and clinical studies200860889991410.1016/j.addr.2007.11.0102-s2.0-42649145864MaedaH.WuJ.SawaT.MatsumuraY.HoriK.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review2000651-227128410.1016/s0168-3659(99)00248-52-s2.0-0034000453ElzoghbyA. O.SamyW. M.ElgindyN. A.Albumin-based nanoparticles as potential controlled release drug delivery systems2012157216818210.1016/j.jconrel.2011.07.0312-s2.0-84855813140BiY.HaoF.YanG.TengL.LeeR. J.XieJ.Actively targeted nanoparticles for drug delivery to tumor201617876378210.2174/13892002176661606191918532-s2.0-84989315866SchroederA.HellerD. A.WinslowM. M.DahlmanJ. E.PrattG. W.LangerR.JacksT.AndersonD. G.Treating metastatic cancer with nanotechnology2012121395010.1038/nrc31802-s2.0-84555178913DongX.MumperR. J.Nanomedicinal strategies to treat multidrug-resistant tumors: current progress20105459761510.2217/nnm.10.352-s2.0-77953368844CampbellR. B.Tumor physiology and delivery of nanopharmaceuticals20066650351210.2174/1871520067786990772-s2.0-33750806589HobbsS. K.MonskyW. L.YuanF.RobertsW. G.GriffithL.TorchilinV. P.JainR. K.Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment19989584607461210.1073/pnas.95.8.46072-s2.0-0032516078SaijoN.Chemotherapy: the more the better? Overview199740Supplement 1S100S10610.1007/s002800051070BanghamA. D.StandishM. M.WatkinsJ. C.Diffusion of univalent ions across the lamellae of swollen phospholipids196513123825210.1016/s0022-2836(65)80093-62-s2.0-85012373035GindyM. E.Prud'hommeR. K.Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy20096886587810.1517/174252409029329082-s2.0-68149163521TummalaS.KuppusamyG.Satish KumarM. N.PraveenT. K.WadhwaniA.5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer20162382902291010.3109/10717544.2015.11160262-s2.0-84949208708HaleyB.FrenkelE.Nanoparticles for drug delivery in cancer treatment2008261576410.1016/j.urolonc.2007.03.0152-s2.0-37649010361AltunI.SonkayaA.The most common side effects experienced by patients were receiving first cycle of chemotherapy20184781218121930186799LiS. D.HuangL.Nanoparticles evading the reticuloendothelial system: role of the supported bilayer20091788102259226610.1016/j.bbamem.2009.06.0222-s2.0-70349542520CarrstensenH.MüllerR. H.MüllerB. W.Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake199211528929710.1016/0261-5614(92)90006-c2-s2.0-0026496481OwensD. E.3rdPeppasN. A.Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles200630719310210.1016/j.ijpharm.2005.10.0102-s2.0-28844488494LiuP.WangB.LiJ.QiaoW.Multi-anticancer drugs encapsulated in the micelle: a novel chemotherapy to cancer200871337938110.1016/j.mehy.2008.05.0022-s2.0-47549084587SmithA. D.Big moment for nanotech: oncology therapeutics poised for a leap2013http://www.onclive.com/publications/oncology-live/2013/june-2013/big-moment-for-nanotech-oncology-therapeutics-poised-for-a-leapUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02213744?termUS National Library of Medicine2014ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01702129?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02112656?termInmanS. F.Approves second-line MM-398 regimen for metastatic pancreatic cancer2015OncLive http://www.onclive.com/web-exclusives/fda-approves-mm-398-regimen-for-metastatic-pancreatic-cancerUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00361842?termUS National Library of Medicine2008ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00377936?termUS National Library of Medicine2012ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00448305?termStathopoulosG. P.AntoniouD.DimitroulisJ.MichalopoulouP.BastasA.MarosisK.StathopoulosJ.ProvataA.YiamboudakisP.VeldekisD.LolisN.GeorgatouN.ToubisM.PappasC.TsoukalasG.Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial201021112227223210.1093/annonc/mdq2342-s2.0-77955198073US National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01591356?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02191878?termUS National Library of Medicine2015ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00409188?termUS National Library of Medicine2015ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01095848?termUS National Library of Medicine2012ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01052142?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01808638?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02314052?termUS National Library of Medicine2011ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00882180?termUS National Library of Medicine2012ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01158079?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01505153?termUS National Library of Medicine2012ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00356980?termCapekI.Polymer decorated gold nanoparticles in nanomedicine conjugates201724938639910.1016/j.cis.2017.01.0072-s2.0-85014098117MotomuraM.IchiharaH.MatsumotoY.Nano-chemotherapy using cationic liposome that strategically targets the cell membrane potential of pancreatic cancer cells with negative charge20182871161116510.1016/j.bmcl.2018.03.0132-s2.0-85043312828BhowmikS.BhowmickS.MaitiK.ChakraA.ShahiP.JainD.RajamannarT.Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer201882352153210.1007/s00280-018-3643-32-s2.0-85049665584QuM. H.ZengR. F.FangS.DaiQ. S.LiH. P.LongJ. T.Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer20144741-211212210.1016/j.ijpharm.2014.08.0192-s2.0-84906691847BrownS.KhanD. R.The treatment of breast cancer using liposome technology20122012621296510.1155/2012/212965ParkJ. W.Liposome-based drug delivery in breast cancer treatment2002439510.1186/bcr4322-s2.0-0036096806MandalA.BishtR.RupenthalI. D.MitraA. K.Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies20172489611610.1016/j.jconrel.2017.01.0122-s2.0-85009516206BarenholzY.(. C.).Doxil®—the first FDA-approved nano-drug: lessons learned2012160211713410.1016/j.jconrel.2012.03.0202-s2.0-84861669644PereiraN. R. C.LoiolaR. A.RodriguesS. F.de OliveiraC. P.BüttenbenderS. L.GuterresS. S.PohlmannA. R.FarskyS. H.Mechanisms of the effectiveness of poly(ε-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment2018134563457310.2147/ijn.s1684002-s2.0-85053736397GanassinR.HorstF. H.CamargoN. S.ChavesS. B.MoraisP. C.Mosiniewicz-SzablewskaE.SuchockiP.LongoJ. P. F.AzevedoR. B.MuehlmannL. A.Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo201846Supplement 21046105210.1080/21691401.2018.14784232-s2.0-85047950658ChenY.AngelovaA.AngelovB.DrechslerM.GaramusV. M.Willumeit-RömerR.ZouA.Sterically stabilized spongosomes for multidrug delivery of anticancer nanomedicines20153397734774410.1039/c5tb01193k2-s2.0-84942852277AstierA.DoatB.FerrerM. J.BenoitG.FleuryJ.RollandA.LevergeR.Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells1988487183518412894892PoupaertJ. H.CouvreurP.A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles2003921-2192610.1016/s0168-3659(03)00177-92-s2.0-0141741672ChavanpatilM. D.KhdairA.GerardB.BachmeierC.MillerD. W.ShekharM. P. V.PanyamJ.Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux20074573073810.1021/mp070024d2-s2.0-35548987443OuY.ChenK.CaiH.ZhangH.GongQ.WangJ.ChenW.LuoK.Enzyme/pH-sensitive polyHPMA-DOX conjugate as a biocompatible and efficient anticancer agent2018651177118810.1039/c8bm00095f2-s2.0-85046257845KopecekJ.KopeckovaP.MinkoT.LuZ.HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action2000501618110.1016/s0939-6411(00)00075-82-s2.0-0041181628MinkoT.KopečkováP.KopečekJ.Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells199916798699610.1023/A:10189590291862-s2.0-0032766043MinkoT.KopečkováP.KopečekJ.Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line199959213314810.1016/s0168-3659(98)00186-22-s2.0-0344142519MinkoT.KopečkováP.KopečekJ.Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells200171322723710.1016/s0168-3659(01)00220-62-s2.0-0035962380DranitsarisG.YuB.WangL.SunW.ZhouY.KingJ.KauraS.ZhangA.YuanP.Abraxane® versus Taxol® for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective201622220521110.1177/10781552145560082-s2.0-84959292742ParkJ.ParkJ. E.HedrickV. E.WoodK. V.BonhamC.LeeW.YeoY.A comparative in vivo study of albumin-coated paclitaxel nanocrystals and Abraxane20181416, article 170367010.1002/smll.2017036702-s2.0-85044340392BhattacharyyaJ.BellucciJ. J.WeitzhandlerI.McDanielJ. R.SpasojevicI.LiX.LinC.-C.ChiJ.-T. A.ChilkotiA.A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models201561, article 793910.1038/ncomms89392-s2.0-84938634258GradisharW. J.TjulandinS.DavidsonN.ShawH.DesaiN.BharP.HawkinsM.O'ShaughnessyJ.Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer200523317794780310.1200/jco.2005.04.9372-s2.0-32944482677LiuC.HaoJ.WuZ.Phase behavior and rheological properties of salt-free catanionic surfactant mixtures in the presence of bile acids2010114309795980410.1021/jp103916a2-s2.0-77955441433GoncalvesA.RoiS.NowickiM.DhaussyA.HuertasA.AmiotM. J.ReboulE.Fat-soluble vitamin intestinal absorption: absorption sites in the intestine and interactions for absorption201517215516010.1016/j.foodchem.2014.09.0212-s2.0-84907546142SugaharaT.TakamatsuY.BhadaniA.AkamatsuM.SakaiK.AbeM.SakaiH.Characterization of the micelle structure of oleic acid-based gemini surfactants: effect of stereochemistry201820138874888010.1039/c8cp00396c2-s2.0-85044831340KlooverJ. S.den BakkerM. A.GelderblomH.van MeerbeeckJ. P.Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens200490230430510.1038/sj.bjc.66013032-s2.0-84934851038RijckenC. J. F.SogaO.HenninkW. E.van NostrumC. F.Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery2007120313114810.1016/j.jconrel.2007.03.0232-s2.0-34447302274LvY.YangB.LiY. M.HeF.ZhuoR. X.Folate-conjugated amphiphilic block copolymer micelle for targeted and redox-responsive delivery of doxorubicin20182919210610.1080/09205063.2017.14001462-s2.0-85033375131ChoucairA.SooP. L.EisenbergA.Active loading and tunable release of doxorubicin from block copolymer vesicles200521209308931310.1021/la050710o2-s2.0-26444459958Sakai-KatoK.NanjoK.KusuharaH.NishiyamaN.KataokaK.KawanishiT.OkudaH.GodaY.Effect of knockout of Mdr1a and Mdr1b ABCB1 genes on the systemic exposure of a doxorubicin-conjugated block copolymer in mice20151293175318310.1021/acs.molpharmaceut.5b002342-s2.0-84941061319BatrakovaE. V.LiS.VinogradovS. V.AlakhovV. Y.MillerD. W.KabanovA. V.Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization2001299248349311602658ZhongZ.RosenowM.XiaoN.SpetzlerD.Profiling plasma extracellular vesicle by pluronic block-copolymer based enrichment method unveils features associated with breast cancer aggression, metastasis and invasion201871, article 145857410.1080/20013078.2018.14585742-s2.0-85045137496PawarA.SinghS.RajalakshmiS.ShaikhK.BothirajaC.Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting201846Supplement 134736110.1080/21691401.2018.14239912-s2.0-85041098879BirhanuG.TanhaS.JavarH. A.SeyedjafariE.Zandi-KarimiA.DehkordiB. K.Dexamethasone loaded multi-layer poly-l-lactic acid/pluronic P123 composite electrospun nanofiber scaffolds for bone tissue engineering and drug delivery201924333834710.1080/10837450.2018.14814292-s2.0-85049121752QinL.WuL.JiangS.YangD.HeH.ZhangF.ZhangP.Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin201826428929510.1080/1061186x.2017.13795252-s2.0-85041580204EmamiJ.RezazadehM.MashayekhiM.RostamiM.Jahanian-NajafabadiA.A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation201844572974010.1080/03639045.2017.14119402-s2.0-85039034531BaoY.YinM.HuX.ZhuangX.SunY.GuoY.TanS.ZhangZ.A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery201623518219410.1016/j.jconrel.2016.06.0032-s2.0-84974578050QiY.QinX.YangC.WuT.QiaoQ.SongQ.ZhangZ.Micelle system based on molecular economy principle for overcoming multidrug resistance and inhibiting metastasis20181531005101610.1021/acs.molpharmaceut.7b009222-s2.0-85043271162BatrakovaE. V.LiS.BrynskikhA. M.SharmaA. K.LiY.BoskaM.GongN.MosleyR. L.AlakhovV. Y.GendelmanH. E.Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers2010143329030110.1016/j.jconrel.2010.01.0042-s2.0-77952242570AlakhovaD. Y.RapoportN. Y.BatrakovaE. V.TimoshinA. A.LiS.NichollsD.AlakhovV. Y.KabanovA. V.Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers201014218910010.1016/j.jconrel.2009.09.0262-s2.0-76749086452BuchholzT. A.StiversD. N.StecJ.AyersM.ClarkE.BoltA.SahinA. A.SymmansW. F.HessK. R.KuererH. M.ValeroV.HortobagyiG. N.PusztaiL.Global gene expression changes during neoadjuvant chemotherapy for human breast cancer20028646146810.1097/00130404-200211000-000102-s2.0-0036836249CarvalhoC.SantosR. X.CardosoS.CorreiaS.OliveiraP. J.SantosM. S.MoreiraP. I.Doxorubicin: the good, the bad and the ugly effect200916253267328510.2174/0929867097888033122-s2.0-70450215499CaoC.LuS.KivlinR.WallinB.CardE.BagdasarianA.TamakloeT.ChuW.-m.GuanK.-l.WanY.AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes200828343288972890810.1074/jbc.m8041442002-s2.0-57649231164JonesR. G.PlasD. R.KubekS.BuzzaiM.MuJ.XuY.BirnbaumM. J.ThompsonC. B.AMP-activated protein kinase induces a p53-dependent metabolic checkpoint200518328329310.1016/j.molcel.2005.03.0272-s2.0-20844449238GwinnD. M.ShackelfordD. B.EganD. F.MihaylovaM. M.MeryA.VasquezD. S.TurkB. E.ShawR. J.AMPK phosphorylation of raptor mediates a metabolic checkpoint200830221422610.1016/j.molcel.2008.03.0032-s2.0-42949139481AlthubitiM.RadaM.SamuelJ.EscorsaJ. M.NajeebH.LeeK. G.LamK.-P.JonesG. D. D.BarlevN. A.MacipS.BTK modulates p53 activity to enhance apoptotic and senescent responses201676185405541410.1158/0008-5472.can-16-06902-s2.0-84988945525GregoryA.KurianM. A.MaherE. R.HogarthP.HayflickS. J.PagonR. A.AdamM. P.ArdingerH. H.WallaceS. E.AmemiyaA.LJHB.PLA2G6-Associated Neurodegeneration1993Seattle (WA)University of WashingtonLiuL. F.DuannP.LinC. T.D'ArpaP.WuJ.Mechanism of action of camptothecin19968031 The Camptothe444910.1111/j.1749-6632.1996.tb26375.x2-s2.0-0030481607WangJ.GohB.LuW.ZhangQ.ChangA.LiuX. Y.TanT. M. C.LeeH. S.In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells200528582282810.1248/bpb.28.8222-s2.0-19644369801WuJ.LuY.LeeA.PanX.YangX.ZhaoX.LeeR. J.Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil200710335035717727798de Oliveira SilvaJ.MirandaS. E. M.LeiteE. A.de Paula SabinoA.BorgesK. B. G.CardosoV. N.CassaliG. D.GuimarãesA. G.OliveiraM. C.de BarrosA. L. B.Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: a preclinical approach201835216216910.1016/j.taap.2018.05.0372-s2.0-85048499659GangulyA.YangH.CabralF.Paclitaxel-dependent cell lines reveal a novel drug activity20109112914292310.1158/1535-7163.mct-10-05522-s2.0-78649660076NganV. K.BellmanK.HillB. T.WilsonL.JordanM. A.Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine200160122523210.1124/mol.60.1.2252-s2.0-0034960408JordanM. A.HimesR. H.WilsonL.Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro1985456274127473986806NganV. K.BellmanK.PandaD.HillB. T.JordanM. A.WilsonL.Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules200060185045505111016627JordanM. A.ThrowerD.WilsonL.Mechanism of inhibition of cell proliferation by Vinca alkaloids1991518221222222009540DhamodharanR.JordanM. A.ThrowerD.WilsonL.WadsworthP.Vinblastine suppresses dynamics of individual microtubules in living interphase cells1995691215122910.1091/mbc.6.9.12152-s2.0-0029115509PalmerC. G.LivengoodD.WarrenA. K.SimpsonP. J.JohnsonI. S.The action of vincaleukoblastine on mitosis in vitro196020119820110.1016/0014-4827(60)90234-22-s2.0-0001166433GregoryR. K.SmithI. E.Vinorelbine – a clinical review200082121907191310.1054/bjoc.2000.1203UedaK.CardarelliC.GottesmanM. M.PastanI.Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine19878493004300810.1073/pnas.84.9.30042-s2.0-0008632564GilmoreD.SchulzM.LiuR.ZubrisK. A. V.PaderaR. F.CatalanoP. J.GrinstaffM. W.ColsonY. L.Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma20132051684169310.1245/s10434-012-2696-52-s2.0-84878822888ShenJ.SunH.XuP.YinQ.ZhangZ.WangS.YuH.LiY.Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles20133451581159010.1016/j.biomaterials.2012.10.0572-s2.0-84870666240US National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01644890?termPrestaykoA. W.D'AoustJ. C.IssellB. F.CrookeS. T.Cisplatin (cis-diamminedichloroplatinum II)197961173910.1016/s0305-7372(79)80057-22-s2.0-0018748917ShiL.NishiokaW. K.Th'ngJ.BradburyE. M.LitchfieldD. W.GreenbergA. H.Premature p34cdc2 activation required for apoptosis199426351501143114510.1126/science.81087322-s2.0-0028178508ShapiroG. I.HarperJ. W.Anticancer drug targets: cell cycle and checkpoint control1999104121645165310.1172/jci90542-s2.0-0033399453ShapiroG. I.EdwardsC. D.EwenM. E.RollinsB. J.p16INK4A participates in a G1 arrest checkpoint in response to DNA damage199818137838710.1128/mcb.18.1.3782-s2.0-0031594707LingX.ChenX.RiddellI. A.TaoW.WangJ.HollettG.LippardS. J.FarokhzadO. C.ShiJ.WuJ.Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance20181874618462510.1021/acs.nanolett.8b019242-s2.0-85048731692QuanL. M.ZhongY.WengH. H.Synthesis of cell penetrating peptide decorated magnetic nanoparticles loading cisplatin for nasopharyngeal cancer therapy2018321396396810.13201/j.issn.1001-1781.2018.13.001DuranteM.LoefflerJ. S.Charged particles in radiation oncology201071374310.1038/nrclinonc.2009.1832-s2.0-76849100171Barcellos-HoffM. H.ParkC.WrightE. G.Radiation and the microenvironment – tumorigenesis and therapy200551186787510.1038/nrc17352-s2.0-28544438548RaineyM. D.CharltonM. E.StantonR. V.KastanM. B.Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation200868187466747410.1158/0008-5472.can-08-07632-s2.0-54749148734VeugerS. J.CurtinN. J.RichardsonC. J.SmithG. C.DurkaczB. W.Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1200363186008601514522929HicksonI.ZhaoY.RichardsonC. J.GreenS. J.MartinN. M. B.OrrA. I.ReaperP. M.JacksonS. P.CurtinN. J.SmithG. C. M.Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM200464249152915910.1158/0008-5472.can-04-27272-s2.0-9744271049US National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02379845?termDingY.-F.LiS.LiangL.HuangQ.YuwenL.YangW.WangR.WangL.-H.Highly biocompatible chlorin e6-loaded chitosan nanoparticles for improved photodynamic cancer therapy201810129980998710.1021/acsami.8b015222-s2.0-85044670982SharmaP.WagnerK.WolchokJ. D.AllisonJ. P.Novel cancer immunotherapy agents with survival benefit: recent successes and next steps2011111180581210.1038/nrc31532-s2.0-80054875641SharmaP.AllisonJ. P.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential2015161220521410.1016/j.cell.2015.03.0302-s2.0-84927130807SpeiserD. E.RomeroP.Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity201022314415410.1016/j.smim.2010.03.0042-s2.0-77953620919SchreibeltG.TelJ.SliepenK. H. E. W. J.Benitez-RibasD.FigdorC. G.AdemaG. J.de VriesI. J. M.Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy201059101573158210.1007/s00262-010-0833-12-s2.0-77955557963LasaroM. O.ErtlH. C. J.Targeting inhibitory pathways in cancer immunotherapy201022338539010.1016/j.coi.2010.04.0052-s2.0-77953537927US National Library of Medicine2012ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00952692?termUS National Library of Medicine2014ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00860522?termNaldiniL.Gene therapy returns to centre stage2015526757335136010.1038/nature158182-s2.0-84944339068US National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02340156?termHirschL. R.StaffordR. J.BanksonJ. A.SershenS. R.RiveraB.PriceR. E.HazleJ. D.HalasN. J.WestJ. L.Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance200310023135491355410.1073/pnas.22324791002-s2.0-0345686712US National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01733238?termUS National Library of Medicine2016ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02226965?termUS National Library of Medicine2014ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01435720?termUS National Library of Medicine2015ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01262235?termUS National Library of Medicine2013ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00689065?termGaoC.TangF.GongG.ZhangJ.HoiM. P. M.LeeS. M. Y.WangR.pH-responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells2017934125331254210.1039/c7nr03611f2-s2.0-85028801031GaoC.TangF.ZhangJ.LeeS. M. Y.WangR.Glutathione-responsive nanoparticles based on a sodium alginate derivative for selective release of doxorubicin in tumor cells20175122337234610.1039/c6tb03032g2-s2.0-85016137925HanahanD.WeinbergR. A.Hallmarks of cancer: the next generation2011144564667410.1016/j.cell.2011.02.0132-s2.0-79952284127TinkleS.McNeilS. E.MühlebachS.BawaR.BorchardG.BarenholzY. C.TamarkinL.DesaiN.Nanomedicines: addressing the scientific and regulatory gap201413131355610.1111/nyas.124032-s2.0-84898788471